Overview

A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (RemeMG)

Status:
RECRUITING
Trial end date:
2027-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of telitacicept in the treatment of generalized myasthenia gravis.
Phase:
PHASE3
Details
Lead Sponsor:
RemeGen Co., Ltd.
Treatments:
telitacicept